The global fermenters and bioreactors market is expected to reach USD 20.4 billion in 2023 anticipated to grow at a CAGR of 11.3% during the forecast period 2023-2035.

Since their introduction in 1982, biologics have experienced a surge in popularity due to their remarkable therapeutic efficacy, favorable safety profiles, and their capacity to address a wide range of challenging medical conditions. The FDA has, in the past two decades, granted approval to over 170 biopharmaceuticals, while more than 7,500 biological interventions are currently undergoing evaluation in clinical trials. The production of these intricate biomolecules requires specialized bioprocessing equipment designed to maintain optimal conditions?such as temperature, pH levels, dissolved oxygen, fluid delivery, and other critical bioprocess parameters essential for consistent cell growth. Bioreactors play a crucial role in the upstream manufacturing processes by creating and sustaining these ideal conditions. Their design aims to amplify the concentration of viable cells, enabling large-scale production of recombinant proteins such as vaccines, fusion proteins, antibodies, and enzymes.

Bioreactors are not limited solely to conventional therapeutic proteins; they also possess the capability to produce advanced medicinal products (ATMPs) like cell and gene therapies, retroviral vectors for gene therapy, and cellular components used in 3D tissue engineering. Conversely, fermenters are utilized for the anaerobic cultivation of microbial cell populations?whether fungal or bacterial?to generate biologics that do not require significant post-translational modifications. Importantly, utilizing fermenters for biologics manufacturing offers numerous advantages over bioreactors. This approach results in faster development, higher quality, increased production output, reduced batch-to-batch variation, enhanced scalability, and lower overall production costs compared to manufacturing in bioreactors.

Report Coverage
? An executive summary of the insights captured during our research, offering a high-level view on the current state of the global bioreactors and fermenters market and its likely evolution in the mid-long term.
? A general introduction to bioreactors and fermenters, along with details related to the components of a bioreactor. Additionally, the chapter presents information on different types of bioreactors based on type of bioprocess and mode of action. Further, it concludes with a discussion on applications of bioreactors and future perspectives in this domain.
? Detailed assessment of the overall market landscape of companies manufacturing bioreactors and fermenters, based on several relevant parameters, such as year of establishment, company size, region of headquarters, geographical reach, type of product, capacity, scale of operation, scalability, type of bioprocess, type of cell culture, mode of operation and type of end user.
? A detailed competitiveness analysis of bioreactor and fermenter manufacturers based on manufacturer strength (in terms of years of experience and company size), portfolio strength (considering geographical reach, type of product, number of products in portfolio, type of bioreactor or fermenter, capacity, scale of operation, scalability, type of bioprocess, type of cell culture, mode of operation and end users).
? Elaborated profiles of key players manufacturing bioreactors and fermenters (shortlisted on the basis of cumulative strength of manufacturers and product portfolio); each profile includes a brief overview of the company, along with information on its financial information (if available), product portfolio, recent developments and an informed future outlook.
? An estimate of the global installed bioreactors and fermenters capacity of biologics, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of fabrication material, source of cell culture, reactor volume, type of manufacturer and key geographical regions
? A case study on the market landscape of bioprocess controllers and automation systems, providing information on scale of operation, key features, compatibility with bioreactor system, type of bioprocess, and type of process controlled.
? A comprehensive market forecast analysis, highlighting the future potential of the market till 2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of product, fabrication material, type of bioprocess, type of biologic and key geographical regions.

Key Market Companies
? Applikon Biotechnology
? Bionet
? Cytiva
? Eppendorf
? Merck
? Ollital Technology
? Parr Instrument Company
? Sartorius
? Shanghai Bailun Biological Technology
? Solaris Biotech
? Solida Biotech
? Zhengzhou Laboao Instrument Equipment (LABAO)